GlassScriptPhysician profile
Brooke E Warnecke
NPI 1538643614
$1,561.59
in general payments reported to CMS, 2019-2025
20 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $504 · 2023: $436 · 2024: $109 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.14 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.98 | 2021-2025 | |
| Novo Nordisk INC | $209.33 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $140.71 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $103.53 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.04 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $50.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.92 | 2022-2023 | |
| Glaxosmithkline, LLC. | $42.41 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $38.73 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $36.37 | 2021-2022 | |
| Amgen INC. | $31.71 | 2022-2025 | Evenity |
| Nestle Healthcare Nutrition INC. | $31.36 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $30.02 | 2023 | Rexulti |
| Lilly USA, LLC | $25.28 | 2022 | |
| Aimmune Therapeutics, INC. | $21.53 | 2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.45 | 2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $13.15 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $12.50 | 2021 | |
| Amarin Pharma, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Warnecke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.